South Delhi Pharma, New Delhi, India
ZEPOSIA ® (ozanimod) capsules, for oral use.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
ZEPOSIA is a prescription medicine. ZEPOSIA is used for multiple sclerosis-MS treatment.
INDICATIONS AND USAGE
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
DOSAGE FORMS & STRENGTHS
Capsules: 0.23 mg, 0.46 mg, 0.92 mg
Manufactured By: Celgene Corporation
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “ZEPOSIA ® (ozanimod) capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Ozanimod, sold under the brand name Zeposia, is an immunomodulatory drug for the treatment of relapsing multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.] It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation. Ozanimod was discovered by The Scripps Research Institute in San Diego, by the labs of Hugh Rosen and Edward Roberts, and licensed to the biotech company Receptos Inc.
Ozanimod was approved for medical use in the United States in March 2020, in the European Union in May 2020, and in Australia in July 2020.
